Abstract #1009

Microstructural Diffusion-Weighted (VERDICT) MRI Metrics are Repeatable and Show Potential at Characterising Gleason 7 Prostate Cancer Non-Invasively

Edward William Johnston¹, Elisenda Bonet-Carne², Hayley Pye³, Joey Clemente¹, Ben Yvernault², Dominic Patel⁴, Susan Heavey³, Mrishta B Appayya¹, Alexandra Saborowska⁵, Ashwin Sridhar⁶, Greg Shaw⁶, Sebastien Ourselin², David Hawkes², Caroline Moore⁶, Hayley Whitaker³, Manuel Rodriguez-Justo⁴, Alexander Freeman⁴, Eleftheria Panagiotaki², Daniel Alexander², and Shonit Punwani¹

¹Centre for Medical Imaging, University College London, London, United Kingdom, ²Centre for Medical Image Computing, University College London, London, United Kingdom, ³Research Department for Tissue & Energy, University College London, London, United Kingdom, ⁴Department of Pathology, University College London Hospital, University Street, United Kingdom, ⁵Radiology, University College London Hospitals, London, United Kingdom, ⁶Department of Urology, University College London Hospital, London, United Kingdom

In this study we we assess the repeatability of VERDICT (Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumours) MRI parameters in prostate cancer consider their ability to distinguish between Gleason grades compared with the standard ADC model in 71 patients. Four of the parametric maps derived from the VERDICT technique were found to be satisfactorily repeatable for use as a clinical tool, and are capable of identifying a Gleason 7 component in prostate cancer where ADC failed to do so. VERDICT therefore holds great potential for use in clinical prostate cancer management pathways in the future.

This abstract and the presentation materials are available to members only; a login is required.

Join Here